Opko Health Inc. (NASDAQ:OPK) shares gapped up prior to trading on Monday . The stock had previously closed at $2.63, but opened at $2.69. Opko Health shares last traded at $2.74, with a volume of 5082601 shares traded.
A number of brokerages recently commented on OPK. Barrington Research restated a “buy” rating and issued a $7.00 price target on shares of Opko Health in a research report on Monday, November 12th. Zacks Investment Research upgraded Opko Health from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a research report on Friday, November 30th. Finally, ValuEngine upgraded Opko Health from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. Opko Health presently has a consensus rating of “Hold” and a consensus target price of $9.50.
The company has a debt-to-equity ratio of 0.03, a current ratio of 0.91 and a quick ratio of 0.78. The stock has a market cap of $1.58 billion, a PE ratio of -9.45 and a beta of 2.09.
Opko Health (NASDAQ:OPK) last released its earnings results on Friday, November 9th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.03. Opko Health had a negative return on equity of 8.68% and a negative net margin of 30.24%. The firm had revenue of $250.00 million for the quarter, compared to analysts’ expectations of $264.04 million. During the same quarter in the previous year, the business posted ($0.08) earnings per share. The business’s revenue for the quarter was up 1.6% on a year-over-year basis. As a group, equities analysts expect that Opko Health Inc. will post -0.22 earnings per share for the current fiscal year.
In other news, Vice Chairman Jane Ph D. Hsiao purchased 10,000 shares of the business’s stock in a transaction dated Thursday, January 31st. The shares were purchased at an average cost of $7.96 per share, with a total value of $79,600.00. Following the completion of the purchase, the insider now owns 24,455,147 shares of the company’s stock, valued at approximately $194,662,970.12. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Phillip Md Et Al Frost purchased 15,000 shares of the business’s stock in a transaction dated Monday, January 14th. The shares were purchased at an average cost of $3.74 per share, for a total transaction of $56,100.00. Following the completion of the purchase, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $11,477,876.74. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 650,000 shares of company stock worth $2,104,100. Company insiders own 42.74% of the company’s stock.
Several institutional investors have recently bought and sold shares of OPK. Diversified Trust Co acquired a new position in shares of Opko Health in the fourth quarter worth approximately $30,000. FDx Advisors Inc. acquired a new position in shares of Opko Health in the fourth quarter worth approximately $33,000. Douglas Lane & Associates LLC acquired a new position in shares of Opko Health in the fourth quarter worth approximately $42,000. Kovack Advisors Inc. acquired a new position in shares of Opko Health in the fourth quarter worth approximately $48,000. Finally, Cumberland Advisors Inc. acquired a new position in shares of Opko Health in the fourth quarter worth approximately $59,000. 24.42% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Opko Health (OPK) Shares Gap Up to $2.69” was first published by Highlight Press and is the sole property of of Highlight Press. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://highlightpress.com/2019/02/11/opko-health-opk-shares-gap-up-to-2-69.html.
About Opko Health (NASDAQ:OPK)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
Featured Article: Google Finance
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.